Back to Newsroom
Back to Newsroom

LAWSUITS FILED AGAINST RECAF, ONTF and SBTX - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

Wednesday, 10 November 2021 06:00 AM

Jakubowitz Law

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / November 10, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Reconnaissance Energy Africa Ltd. f/k/a Lund Enterprises Corp. (OTCQX:RECAF)

CONTACT JAKUBOWITZ ABOUT RECAF:
https://claimyourloss.com/securities/reconnaissance-energy-africa-ltd-f-k-a-lund-enterprises-corp-loss-submission-form/?id=21002&from=1

Class Period : February 28, 2019 - September 7, 2021

Lead Plaintiff Deadline : December 27, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) ReconAfrica's plan for using unconventional means for energy extraction (including fracking) in the fragile Kavango area; (2) ReconAfrica would begin unlicensed drilling tests; (3) ReconAfrica would illegally use water for well testing; (4) ReconAfrica would illegally store used water in unlined pools; (5) ReconAfrica would skirt Namibian law and hire an inadequate and inappropriate consultant; (6) as a result, ReconAfrica risked future well, drilling, and water-related licenses in Namibia and Botswana; (7) as opposed to its representations, ReconAfrica did not reach out nor provide adequate information (including in relevant local languages) through accessible means to those to be impacted by its testing and potential energy extraction; (8) ReconAfrica's interests are in the Owambo Basin, not the so-called Kavango Basin; (9) ReconAfrica has continuously engaged in stock pumping; and (10) as a result of the foregoing, Defendants' public statements were materially false and/or misleading at all relevant times.

On24, Inc. (NYSE:ONTF)

CONTACT JAKUBOWITZ ABOUT ONTF:
https://claimyourloss.com/securities/on24-inc-loss-submission-form/?id=21002&from=1

This lawsuit is on behalf of persons and entities who also acquired ON24's shares pursuant and traceable to the Offering issued in connection with the Company's February 2, 2021, initial public offering.

Lead Plaintiff Deadline : January 3, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the surge in COVID-19 customers observed in the lead up to the IPO consisted of a significant number that did not fit ON24's traditional customer profile, and, as a result, were significantly less likely to renew their contracts.

Silverback Therapeutics, Inc. (NASDAQ:SBTX)

CONTACT JAKUBOWITZ ABOUT SBTX:
https://claimyourloss.com/securities/silverback-therapeutics-inc-loss-submission-form/?id=21002&from=1

This lawsuit is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Silverback common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about December 3, 2020 and/or (b) Silverback securities between December 3, 2020 and September 10, 2021, both dates inclusive.

Lead Plaintiff Deadline : January 4, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Silverback's lead product candidate SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers, was less effective than the Company had represented to investors; (ii) accordingly, the Company had overstated SBT6050's commercial and/or clinical prospects; and (iii) as a result, the Offering Documents and Defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein.

Jakubowitz Law, Wednesday, November 10, 2021, Press release picture

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

Topic:
Lawsuits
Back to newsroom
Back to Newsroom

Contact Us Today


If you have questions or want to learn more about our products, our team’s here to help!

Share by: